| Name | IPI-9119 |
| Description | IPI-9119 is an orally active, selective, and irreversible FASN inhibitor (IC50 = 0.3 nM). |
| In vitro | IPI-9119 (0.05, 0.1, 0.25, 0.5, 5 μM; 6 days) inhibits AR-FL and AR-V7 protein expression. IPI-9119 (0.1, 0.5 μM; 6 days) inhibits cell growth and induces cell cycle arrest and apoptosis[1]. IPI-9119 inhibits FASN in cellular occupancy assays (IC50∼10nM) and shows more than 400-fold selectivity against several additional serine hydrolases[2]. |
| In vivo | IPI-9119 inhibits tumor growth of castration-resistant prostate cancer in xenografts mouse models[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 95 mg/mL (191.75 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (6.66 mM), Sonication is recommended.
|
| Keywords | prostate | orally | LNCaP-95 | LNCaP | irreversible | IPI-9119 | IPI9119 | IPI 9119 | Inhibitor | inhibit | FattyAcidSynthase | Fatty Acid Synthase (FASN) | Fatty Acid Synthase | CRPC | castration-resistant | cancer | C4-2 | AR-V7 | AR-FL | 22Rv1 |
| Inhibitors Related | Betulin | Fatostatin hydrobromide | Denifanstat | Pyrazinamide | A-769662 | VY-3-135 | Orlistat | trans-Chalcone | TVB-3664 | L-Carnitine | Lycorine | FASN-IN-1 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Obesity Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |